Could a blood vessel drug help tame giant cell arteritis?

NCT ID NCT06957002

First seen May 10, 2026 · Last updated May 30, 2026 · Updated 8 times

Summary

This study tests whether adding bosentan to standard steroid treatment helps people with giant cell arteritis (GCA) stay relapse-free longer and use less steroids. About 40 adults with GCA will receive either bosentan plus steroids or steroids alone for 3 months, then be followed for a year. The goal is to see if the combination reduces flares and allows safer steroid tapering.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GIANT CELL ARTERITIS (GCA) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Unité de Recherche Clinique, Entrepôts de données et Pharmacologie GHU Paris Centre

    Paris, 75005, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.